Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study.
HIV
Myanmar
epidemiology
hepatitis C
sustained virologic response
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
24
11
2022
revised:
04
02
2023
accepted:
07
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplification of HCV service delivery through task-shifting among health workers and decentralization to the primary health care level. Between November 2016 and November 2017, a study was conducted to describe the epidemiological data and real-world outcomes of treating HIV/HCV coinfected patients with generic direct acting antiviral (DAA) based regimens in the three HIV clinics run by nonspecialist medical doctors in Myanmar. HCV co-infection among people living with HIV (PLHIV) from two clinics in Yangon city and one clinic in Dawei city was screened by rapid diagnostic tests and confirmed by testing for viral RNA. Nonspecialist medical doctors prescribed sofosbuvir and daclatasvir based regimens (with or without ribavirin) for 12 or 24 weeks based on the HCV genotype and liver fibrosis status. Sustained virologic response at 12 weeks after treatment (SVR12) was assessed to determine cure. About 6.5% (1417/21,777) of PLHIV were co-infected with HCV. Of 864 patients enrolled in the study, 50.8% reported history of substance use, 27% history of invasive medical procedures and 25.6% history of incarceration. Data on treatment outcomes were collected from 267 patients of which 257 (96.3%) achieved SVR12, 7 (2.6%) failed treatment, 2 (0.7%) died and 1 (0.4%) became loss to follow-up. The study results support the integration of hepatitis C diagnosis and treatment with DAA-based regimens into existing HIV clinics run by nonspecialist medical doctors in a resource-limited setting. Epidemiological data on HIV/HCV co-infection call for comprehensive HCV care services among key populations like drug users and prisoners in Yangon and Dawei.
Sections du résumé
Background and Aims
UNASSIGNED
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplification of HCV service delivery through task-shifting among health workers and decentralization to the primary health care level. Between November 2016 and November 2017, a study was conducted to describe the epidemiological data and real-world outcomes of treating HIV/HCV coinfected patients with generic direct acting antiviral (DAA) based regimens in the three HIV clinics run by nonspecialist medical doctors in Myanmar.
Methods
UNASSIGNED
HCV co-infection among people living with HIV (PLHIV) from two clinics in Yangon city and one clinic in Dawei city was screened by rapid diagnostic tests and confirmed by testing for viral RNA. Nonspecialist medical doctors prescribed sofosbuvir and daclatasvir based regimens (with or without ribavirin) for 12 or 24 weeks based on the HCV genotype and liver fibrosis status. Sustained virologic response at 12 weeks after treatment (SVR12) was assessed to determine cure.
Results
UNASSIGNED
About 6.5% (1417/21,777) of PLHIV were co-infected with HCV. Of 864 patients enrolled in the study, 50.8% reported history of substance use, 27% history of invasive medical procedures and 25.6% history of incarceration. Data on treatment outcomes were collected from 267 patients of which 257 (96.3%) achieved SVR12, 7 (2.6%) failed treatment, 2 (0.7%) died and 1 (0.4%) became loss to follow-up.
Conclusion
UNASSIGNED
The study results support the integration of hepatitis C diagnosis and treatment with DAA-based regimens into existing HIV clinics run by nonspecialist medical doctors in a resource-limited setting. Epidemiological data on HIV/HCV co-infection call for comprehensive HCV care services among key populations like drug users and prisoners in Yangon and Dawei.
Identifiants
pubmed: 36819986
doi: 10.1002/hsr2.1119
pii: HSR21119
pmc: PMC9938359
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1119Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Liver Int. 2021 Nov;41(11):2578-2589
pubmed: 34153155
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Trop Doct. 2013 Jul;43(3):113-5
pubmed: 23800421
Open Forum Infect Dis. 2019 Mar 23;6(4):ofz100
pubmed: 30949539
BMC Infect Dis. 2018 Dec 14;18(1):657
pubmed: 30547747
J Viral Hepat. 2010 Apr;17(4):280-6
pubmed: 19732322
J Hepatol. 2015 Jul;63(1):199-236
pubmed: 25911336
J Viral Hepat. 2021 Jan;28(1):147-158
pubmed: 32935438
Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):247-66
pubmed: 24450362
Hepatol Int. 2018 Sep;12(5):465-473
pubmed: 30203381
J Clin Exp Hepatol. 2019 May-Jun;9(3):283-293
pubmed: 31360020
J Viral Hepat. 2020 Sep;27(9):886-895
pubmed: 32358826
World J Hepatol. 2015 Dec 8;7(28):2829-33
pubmed: 26668694
PLoS One. 2018 Jun 6;13(6):e0197544
pubmed: 29874250
J Viral Hepat. 2019 Oct;26(10):1186-1199
pubmed: 31104344